

Corrigendum

The authors regret that there were errors in the original version of the following issue of the *Health Technology Assessment* journal:

Reference

Wyatt K, Henley W, Anderson L, Anderson R, Nikolaou V, Stein K, *et al.* The effectiveness and cost of enzyme replacement and substrate reduction therapies: a longitudinal cohort study of people with lysosomal storage disorders. *Health Technol Assess* 2012;**16**(39).

Pages a, i and v

Original title

The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders

Correction

The effectiveness and cost of enzyme replacement and substrate reduction therapies: a longitudinal cohort study of people with lysosomal storage disorders

Page v

Original

Objectives: To determine natural history and estimate effectiveness and cost of enzyme replacement therapy (ERT) and substrate replacement therapy (SRT) for patients with Gaucher disease, Fabry disease, mucopolysaccharidosis type I (MPS I), mucopolysaccharidosis type II (MPS II), Pompe disease and Niemann–Pick type C (NPC) disease.

Correction

Objectives: To determine natural history and estimate effectiveness and cost of enzyme replacement therapy (ERT) and substrate reduction therapy (SRT) for patients with Gaucher disease, Fabry disease, mucopolysaccharidosis type I (MPS I), mucopolysaccharidosis type II (MPS II), Pompe disease and Niemann–Pick type C (NPC) disease.